Comparing targeted exome and whole exome approaches for genetic diagnosis of neuromuscular disorders  by Gorokhova, Svetlana et al.
Applied & Translational Genomics 7 (2015) 26–31
Contents lists available at ScienceDirect
Applied & Translational Genomics
j ourna l homepage: www.e lsev ie r .com/ locate /atgComparing targeted exome and whole exome approaches for genetic
diagnosis of neuromuscular disordersSvetlana Gorokhova a,⁎, Mathieu Cerino a,b, Yves Mathieu a, Sébastien Courrier a, Jean-Pierre Desvignes a,
David Salgado a, Christophe Béroud a, Martin Krahn a,b,1, Marc Bartoli a,1
a Aix Marseille University, INSERM, GMGF, UMR_S 910, 13385, Marseille, France
b APHM, Department de Medical Genetics, Timone Children's Hospital, Marseille, France⁎ Corresponding author.
1 These authors have contributed equally.
http://dx.doi.org/10.1016/j.atg.2015.07.006
2212-0661/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 7 July 2015
Received in revised form 30 July 2015
Accepted 31 July 2015
Keywords:
Targeted exome
Gene panel
Whole exome
Massively parallel sequencing
Genetic diagnosis
Neuromuscular disordersMassively parallel sequencing is rapidly becoming awidely usedmethod in genetic diagnostics. However, there is
still no clear consensus as to which approach can most efﬁciently identify the pathogenic mutations carried by a
given patient, while avoiding false negative and false positive results. We developed a targeted exome approach
(MyoPanel2) in order to optimize genetic diagnosis of neuromuscular disorders. Using this approach, we were
able to analyse 306 genes known to bemutated inmyopathies aswell as in related disorders, obtaining 98.8% tar-
get sequence coverage at 20×. Moreover, MyoPanel2 was able to detect 99.7% of 11,467 known mutations re-
sponsible for neuromuscular disorders. We have then used several quality control parameters to compare
performance of the targeted exome approach with that of whole exome sequencing. The results of this pilot
study of 140 DNA samples suggest that targeted exome sequencing approach is an efﬁcient genetic diagnostic
test for most neuromuscular diseases.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Massively parallel sequencing has been widely used in genetic re-
search since it has been developed more than a decade ago. This
technology is also rapidly expanding into the genetic diagnostics
ﬁeld, expected to soon replace the gold-standard Sanger sequencing.
However, a number of recent studies have suggested that adoption of
massively parallel sequencingmethods for genetic diagnosis of patients
must be done with caution, as this technology can have false negative
results due to locus-speciﬁc sequencing bias (Ross et al., 2013) or sub-
optimal variant calling by bioinformatics algorithms (O'Rawe et al.,
2013; Park et al., 2014). Several studies have attempted to asses and
compare the efﬁciency of different massively parallel sequencing
methods (Lelieveld et al., 2015; Xue et al., 2014). However, because of
rapid evolution of this technology as well as inherent differences in
diagnosis between speciﬁc types of genetic disorders, further investiga-
tions are critical to determine the appropriate clinical sequencing ap-
proaches. We have developed an optimized targeted exome test for
genetic diagnosis of neuromuscular diseases. We have then conducted
a pilot study comparing this approach with whole exome sequencing,
suggesting that optimized targeted exome approach is an efﬁcient ge-
netic diagnostic test for this group of disorders.. This is an open access article under2. Materials and methods
2.1. Targeted exome approach design
Two different targeted exome designs are described in this study: the
initial MyoPanel1 and the optimized MyoPanel2 designs. MyoPanel1
targeted exome approach was developed using HaloPlex target en-
richment system (Agilent, CA, USA) adapted for Ion Torrent Next
Generation Sequencing technology and has been recently described
(Sevy et al., 2015). MyoPanel1 was composed of genes implicated
in neuromuscular diseases and cardiomyopathies listed in the Gene
Table of Neuromuscular Disorders (Kaplan and Hamroun, 2013) as
well as differential diagnosis genes (298 genes total). The DNA cap-
ture probes for both MyoPanels were designed using the Agilent
SureDesign web-based application (https://earray.chem.agilent.
com/suredesign/home.htm, June 2015). The target regions used as
an input for SureDesign tool included protein coding exons and
10 bp intron ﬂanking regions. The characteristics of both designs
are shown in Fig. 1D. The following modiﬁcations of MyoPanel1
were done to obtain the optimized MyoPanel2. Three genes were re-
moved from the panel: SMN1 because of low target coverage by the
capture probes proposed by SureDesign, DUX4 and KCNJ18 due to
off-target read alignment. Eleven new genes were added: ALG14,
BICD2, GMPPB, KLHL40, PTPLA, RBCK1, SLC5A7, SMCHD1, TIA1, TNPO3,
and TRAPPC11. Capture probes for 436 regions with poor coverage by
MyoPanel1 were redesigned. Shorter probes were selected for thesethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Optimization of the targeted exome approach. A. IGV visualization of MyoPanel1 HaloPlex probes (grey dashed lines) covering the exons 7 and 8 ofHCN4 gene. Pink and blue lines
correspond to reads (forward and reverse respectively) obtained from the sequencing experiment. Both longer and shorter HaloPlex probes cover exon 8, generating a number of reads.
Only longer (280 bp andmore) probes cover exon 7, producing no reads. PCR primers speciﬁc to the 280 bp probe are shown as black arrows. B. LongerHaloPlex probes are lost during the
emulsion PCR step. PCR using individual probe-speciﬁc primers was performed on aliquots from the following library preparation steps: two different samples before emulsion PCR (S1
and S2), before enrichment (UE),wash solution after elution (W), after enrichment (E). A PCR fragment (119 bp) is ampliﬁedusing primers speciﬁc to a shorter 157 bp control probe,while
no PCR fragment is produced from post-emulsion PCR steps library aliquots using primers speciﬁc to a 280 bp probe (HCN4, exon 7). Similar results were obtained for three other longer
probes. C. IGV visualization of the same region as shown in A for the targeted exomeMyoPanel2. Shorter HaloPlex probes cover exon 7, producing a number of reads. D. Characteristics of
MyoPanel1 and 2 designs.
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of probes designed with the default parameters.
2.2. Identiﬁcation of regions poorly covered by MyoPanel1
Coverage of the target exons was obtained for each sample with the
help of VarAFT tool (http://varaft.eu, June 2015), which uses BedTools
(Quinlan and Hall, 2010) to compute coverage statistics. For each
exon, we veriﬁed whether it was 100% covered at 5× in at least eight
out of ten samples. 436 exons did notmeet this requirement and served
as an input for SureDesign tool to obtain better DNA capture probe
design.
2.3. Detection of longer probes during library preparation steps
PCR using individual probe-speciﬁc primers was performed on al-
iquots from the following library preparation steps: two different
samples before emulsion PCR, before enrichment, wash solution after
elution and after enrichment. The following primerswere used for detec-
tion of a 280 bp probe covering in HCN4 gene - 5'GACCTGGCTTAGGC
ATAAAGG and 5'TCCTGAGTCCTGATGCTCTG producing 270 bp fragment;
for detection of a 400 bp probe in COL6A1 gene - 5'TGTCTGACCTGCAT
CTGACTC and 5'GGCCAATCAACTGTCAGACTT producing a 390 bp frag-
ment; for detection of a 379 bp probe in PNPLA2 gene 5'TAGTGAAGGGA
GGTGGCTGT and 5'CGAGTAATCCTCCGCTTGG producing 370 bp frag-
ment; for detection of a 337 bp probe in LMNA gene 5'GAGATGCGGGC
AAGGATG and 5'ACTCCAGTTTGCGCTTTTTG producing 321b. Primers to
detect a shorter 157 bp control probe in FAT1 gene were 5'CAAGGACT
TCGACTTCCCG and 5'CACTGGTGCCGTGAGTACG producing a 119 bp
fragment.2.4. DNA samples and sequencing experiments
Results from ﬁve sequencing experiments were used for this
study. Experiments 1 (10 DNA samples) and 2 (33 DNA samples) of
MyoPanel1 were performed using HaloPlex (Agilent) capture meth-
od and sequenced on two different in-house PGM (Ion Torrent) se-
quencers. MyoPanel2 experiment was performed using HaloPlex
enrichment method and NextSeq (Illumina) sequencing by Helixio
(Biopôle Clermont-Limagne, France). A total of 46 DNA samples
were sequenced. Of them, 17 DNA samples (batch1) were received
from abroad and were most likely of lower quality, given clear differ-
ences in sequencing results for this batch of samples. No differences
between the batch1 samples and the remaining 29 MyoPanel2 sam-
ples were observed at the time of library preparation. Results from
two different whole exome sequencing experiments were included
in this study, both performed using Agilent SureSelect V4 reagent
kits and HiSeq (Illumina). Experiment 1 included 20 DNA samples
and was sequenced by Integragen Genomic (Evry, France). Experi-
ment 2 included 31 DNA samples andwas sequenced by CNG (Centre
National de Génotypage, Evry, France).2.5. Library preparation, sequencing and variant calling
For MyoPanel1, DNA extraction and library preparation was per-
formed as previously described (Sevy et al., 2015). Brieﬂy, libraries of
DNA samples were created using the Haloplex Target Enrichment Sys-
tem Kit (Agilent Technologies, CA, USA) according tomanufacturer's in-
structions for Ion Torrent sequencing version D4. Emulsion clonal PCR
ampliﬁcationwas performed using the Ion PGM (Personal GenomeMa-
chine) Template OT2 200 kit (Life Technologies, CA, USA) and Ion One
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richment of the ion spheres particles (ISPs) using an Ion One Touch
ES (Life Technologies, CA, USA) enrichment module according to
the manufacturer's instructions. ISPs were loaded on a 318v2 chip
and sequenced using an Ion PGM Sequencing 200 Kit v2 (Life Tech-
nologies, CA, USA) on a PGM sequencer system (Life Technologies,
CA USA). Raw data generated by the PGM sequencer were processed
by Torrent Suite Software v.4 and aligned using TMAPv.3 (https://
github.com/iontorrent/TMAP, June 2015). Sequence variants were
identiﬁed using the VariantCaller tool from the Ion Torrent package
using default “germline high stringency” parameters.
For MyoPanel2, the initial DNA extraction and library preparation
steps were similar to that of MyoPanel1, except that the adaptors
used for creating the libraries of DNA samples with the Haloplex Tar-
get Enrichment System Kit (Agilent Technologies, CA, USA) were
speciﬁc of Illumina sequencing technology. The libraries were then
separated in three different pools for the step of clonal ampliﬁcation
by bridge PCR on the Next Seq 500 followed by paired end sequenc-
ing using the NextSeq 500 Mid Output kit (300 cycles) and the
Illumina two-channel sequencing by synthesis (SBS) technology
(Illumina, CA, USA). Sequencing reads were aligned using BWA-
MEM 0.7.12 (Li and Durbin, 2009) with default parameters and
Hg19 as the reference genome. Sambamba 0.51 (http://lomereiter.
github.io/sambamba/index.html, June 2015) was used to convert
SAM to BAM format. GATK 3.3 (McKenna et al., 2010) was used for
local realignment around indels and for base quality score recalibra-
tion. Variant calling was performed using Haplotype Caller (GATK
3.3), followed by standard hard variant ﬁltering using
VariantFiltration module of GATK 3.3 with cut-offs depth b10 and
quality score b50 according to GATK Best Practices recommenda-
tions (Van der Auwera et al., 2013; DePristo et al., 2011).2.6. Coverage analysis comparison between target exome andwhole exome
approaches
In order to compare the coverage between MyoPanel1, MyoPanel2
and whole-exome results, a set of 295 genes was used. The bed ﬁle for
a set of 5817 unique exons corresponding to the protein coding parts
of these genes and including all the splice variants of RefSeq genes
was downloaded from UCSC Genome Browser using Table Browser op-
tion (Rosenbloom et al., 2015). Coverage and depth statistics for this set
of exons were obtained for each sample using VarAFT tool. Sample p54
was excluded from the analysis due to much lower quality of sequenc-
ing results obtained.2.7. Mutation coverage analysis
A set of 11,467 publishedmutationswas obtained fromLocus Specif-
ic Mutation Databases (http://grenada.lumc.nl/LSDB_list/lsdbs, June
2015) for target regions of 78 genes present in both MyoPanel1 and
Myopanel2. This set was then used to calculate coverage of individual
mutation positions for each sample using VarAFT tool. Number ofmuta-
tions with no coverage, less than 6× coverage and less that 20× cover-
age was calculated.3. Results
We performed a pilot study designed to test and optimize the
targeted exome approach for genetic diagnosis of neuromuscular dis-
eases. Our second goal was to compare the quality of sequencing data
obtained from targeted exome as well as whole-exome experiments
in order to determine which approach was more suitable for genetic
diagnosis.3.1. Optimization of targeted exome design
Our initial targeted exome design, MyoPanel1, was developed to si-
multaneously analyse 298 genes (5972 unique exons) implicated in
neuromuscular disorders. It was tested in two sequencing experiments.
The ﬁrst one, MyoPanel1-exp1, included 10 samples from patients with
known neuromuscular mutations. The second experiment, MyoPanel1-
exp2, included 33 DNA samples from both undiagnosed and control pa-
tients with neuromuscular conditions (Sevy et al., 2015). Detailed cov-
erage analysis from these experiments identiﬁed 436 exons that were
less than 100% covered at 5× in at least eight out of ten samples. We
then examined these low-coverage regions in detail and noticed that
many of themwere designed to be enriched by longer HaloPlex probes.
One such region, exon 7 of HCN4 gene, is shown in Fig. 1A. Indeed, this
exon was covered by design but was not sequenced in the MyoPanel1
experiments. We hypothesized that the longer fragments were lost ei-
ther during one of the library preparation steps or during sequencing.
In order to answer this question, we designed PCR primers speciﬁc to
longer probes covering regions with no corresponding sequencing
reads. Results of PCR ampliﬁcation using primers speciﬁc to a 280 bp
HaloPlex probe on aliquots from several library preparation steps are
shown in Fig. 1B. As seen from these results, the DNA fragments are ini-
tially present, but then lost during the emulsion PCR step. Similar results
were obtained for three longer probes from other genomic regions. Am-
pliﬁcation using primers speciﬁc to a shorter (157 bp) probe produced
PCR products from all library preparation steps. Thus, longer
(N280 bp) HaloPlex probes were lost after the emulsion PCR step, lead-
ing to gaps in obtained sequence coverage. We therefore redesigned
HaloPlex probes for 436 poorly covered regions using FFPE (formalin-
ﬁxed parafﬁn-embedded) option in SureDesign tool. When this option
is selected, shorter probes are designed to compensate for DNA frag-
mentation observed in the formalin-processed samples. We have also
added 11newgenes and removed three genes from thenewMyoPanel2
design: SMN1 because of low target coverage by the probes proposed by
SureDesign,DUX4 and KCNJ18 due to off-target read alignment. In order
to diminish the possibility of losing probes during the emulsion PCR
step and to test a different sequencing method, we have designed the
MyoPanel2 probes for the Illumina platform. The summary of the opti-
mizedMyoPanel2 and the initial MyoPanel1 designs is shown in Fig. 1D.3.2. Quality analysis of MyoPanel2 sequencing results
We have obtained sequencing results for 46 DNA samples using
MyoPanel2 design for targeted exome approach. Many more reads
were obtained for regions that were poorly covered in MyoPanel1 ex-
periments. An example of such region, exon 7 of HCN4 gene, is shown
in Fig. 1C. Interestingly, most of the coverage for this region still comes
from the shorter capture probes, suggesting that improvement in the
coverage ismostly due toprobe re-design andnot just due to the change
in sequencing technology.
The sequence coverage statistics for each sample is shown in Fig. 2A.
A set of 17 DNA samples (batch1) had clearly lower target sequence
coverage comparing to the rest of the DNA samples. These samples all
came from the same source abroad and most likely contained lower
quality DNA. Interestingly, we observed no apparent differences be-
tween this batch and the rest of the samples during numerous quality
checks at different library preparation steps. It is possible that minor
DNAdegradationwas present in these samples, suggesting that an addi-
tional PCR-based DNA integrity veriﬁcation stepmight be necessary be-
fore the library preparation procedure. Average target sequence
coverage in MyoPanel2 experiment was 99.7% at 1×, 99.6% at 5×,
99.3% at 10×, 98.8% at 20× and 98.3% at 30× for high quality DNA sam-
ples. For lower quality (batch1) samples, the coverage was 99.3% at 1×,
98.1% at 5×, 96.8% at 10×, 94.1% at 20× and 91.6% at 30×. Thus, even for
the lower quality DNA samples, the target sequence coverage is
Fig. 2. Coverage and depth statistics for MyoPanel2 sequencing experiment. A. Coverage statistics per sample in MyoPanel2 sequencing experiment. Average coverage was 99.7% at 1×,
99.6% at 5×, 99.3% at 10×, 98.8% at 20× and 98.3% at 30× for high quality DNA samples. For lower quality (batch1) samples, the coverage was 99.3% at 1×, 98.1% at 5×, 96.8% at 10×,
94.1% at 20× and 91.6% at 30×. B. Depth of coverage per sample in MyoPanel2 sequencing experiment. Average depth of coverage was 1106 reads for higher quality DNA samples and
989 reads for lower quality DNA samples.
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(Lelieveld et al., 2015; Biesecker and Green, 2014).
The depth of coverage per sample in MyoPanel2 sequencing ex-
periment is shown in Fig. 2B. Contrary to the sequence coverage sta-
tistics, we did not observe any clear differences in depth between
batch1 and the rest of the samples. An average depth of coverage
was 1106 reads for higher quality DNA samples and 989 reads for
lower quality (batch1) DNA samples. Interestingly, sample quality
had a drastic effect on sequence coverage independently of coverage
depth. For example, samples P68 and P60 had similar depth of se-
quencing (average of 1092 and 1114 reads respectively), while cov-
erage of target regions was much better for P68 comparing to that of
P60 (99.8% and 88.2% respectively at 20×). These results show thatFig. 3. Coverage of knownmutations for MyoPanel2 design. A. Number of knownmutation pos
tions with b6× coverage (red line) in correlation with target sequence coverage (bars) per sam
exome approach. Of these, six are not covered by capture probe design and therefore cannot be
batch1 had many more missed known mutation positions.percentage of target coverage is not directly related to the depth cov-
erage. Thus, increasing the depth of coverage cannot compensate for
lower sample DNA quality.
3.3. Known mutation coverage
Percentage of target region coverage is now a widely accepted qual-
ity control parameter in massively parallel sequencing approaches.
However, even the experiments with high average sequence coverage
can still have a high rate of false negative results if pathogenicmutations
are concentrated in the regions with gaps in sequencing. Thus, for ge-
netic diagnostics, statistics about the coverage of known pathogenic
mutation positions is a key quality control parameter. We analyseditions with no or low sequence coverage per eachMyoPanel2 sample. B. Number of muta-
ple. As little as 12 out 11,467 published mutations are missed by our optimized targeted
detected even if the sequencing conditions are optimal. Lower quality DNA samples from
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11,467 published mutations located in target regions of 78 neuromus-
cular genes. Numbers of known mutation positions missed or covered
at less than 6× and 20× are shown in Fig. 3A. As expected, numbers
of missed mutations are greater in samples with gaps in sequencing
(i.e. sampleswith lower target sequence coverage). In order to better vi-
sualize this relationship, overlay of 20× sequence coverage data (bars)
and the number of known mutation positions covered at less than 6×
(red line) is shown in Fig. 3B. In several samples, as little as 12 out of
11,467 known mutation positions were missed (covered b 6×). Of
these, six mutations cannot be detected by MyoPanel2 since they are
not covered by the capture probes. Many more mutation positions are
not covered in lower quality DNA samples (batch1). These results un-
derline the importance of analysing both target sequence coverage
and known mutation coverage.
3.4. Comparison between targeted and whole exome approaches
We then compared several quality control parameters between
three different targeted exome and two whole exome experiments.
Since target regions differed between MyoPanel1 and MyoPanel2, anFig. 4. Comparison between targeted exomeandwhole exome approaches. A. Percentage of targ
ing to 295 genes found in both MyoPanel1 and MyoPanel2, was used for coverage and dept
MyoPanel1-exp2, 94.1% for lower-quality (batch1) MyoPanel2 samples, 98.8% for other MyoP
Depth of coverage for all sequencing experiments. Average depth of coveragewas 221 forMyoP
1106 for other MyoPanel2 samples, 88 and 104 for two different whole exome sequencing exp
11,467 publishedmutationswas used for calculations. Average number of mutation positions co
lower-quality (batch1) MyoPanel2 samples, 99.7% for other MyoPanel2 samples, 97.1% and 99overlap set of 5817 unique exons (295 genes) was used for coverage
and depth analysis. The same set of exonswas used to calculate the cov-
erage and depth for exomedata. Typical genome and exome sequencing
experiments cover 85 to 95% of the targeted sequence (Biesecker and
Green, 2014), with more recent studies reporting 95% at 20× for
whole exomes (Lelieveld et al., 2015). As seen from Fig. 4A, we observed
similar coverage statistics in two different whole exome experiments:
93.4% and 96% coverage at 20×. Coverage of optimized MyoPanel2
was 98.8%,which is superior to exomes and to initialMyoPanel1 results.
Depth of coverage was much higher for MyoPanel2 experiment
(Fig. 4B). However, as discussed above, depth of coverage did not corre-
late with percentage of target sequence coverage, as seen from the re-
sults for batch1 samples.
In order to assess the ability of each sequencing approach to detect
potential disease-causing mutations, we compared the percentage of
known mutation positions (11,467 total) identiﬁed with more than
1× and 6× coverage. MyoPanel2 was able to detect the highest number
of publishedmutations. Indeed, 99.7% of knownmutation positionswas
detected byMyoPanel2, comparing to 97.1% and99.2% identiﬁed by two
different whole exome sequencing experiments. That is, if a given pa-
tient carried a known pathogenic mutation responsible for theet region coverage for all sequencing experiments. A set of 5817 unique exons, correspond-
h analysis. Average sequence coverage at 20× was 95.5% for MyoPanel1-exp1, 92% for
anel2 samples, 93.4% and 96% for two different whole exome sequencing experiments. B.
anel1-exp1, 195 for MyoPanel1-exp2, 989 for lower-quality (batch1)MyoPanel2 samples,
eriments. C. Percentage of knownmutation positions detected by sequencing test. A set of
veredmore than 6×was 96.2% for MyoPanel1-exp1, 95.7% forMyoPanel1-exp2, 98.1% for
.2% for two different whole exome sequencing experiments. Averages ± SD are shown.
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lower if MyoPanel2 was used for diagnosis. Our results therefore sug-
gest that, based on several quality control parameters, targeted exome
approach is superior to whole exome sequencing for genetic diagnosis
of most neuromuscular disorders.
4. Discussion
In this study we present an optimization process for targeted
exome approach, leading to a more sensitive sequencing test, based
on coverage statistics as well as on percentage of known mutation
positions detected. We have also compared the performance of this
optimized targeted exome approach with whole exome sequencing
using a set of genes mutated in neuromuscular diseases. Using the
optimized targeted exome approach we were able to analyse 306
genes with 98.8% target sequence coverage at 20× and to detect
99.7% of 11,467 known mutations responsible for neuromuscular
disorders. Based on the results of our pilot study, several quality con-
trol parameters for targeted exome approachwere superior to that of
whole exome sequencing (obtained using V4 reagent kits and
HiSeq). It is important to note, however, that as sequencing technol-
ogy continues to evolve rapidly, the newer versions of whole exome
sequencing approach might be more efﬁcient than the one used in
this study.
46% diagnostic rate was observed with our initial targeted exome
approach (MyoPanel1) applied to a cohort of patients affectedwith dis-
tal myopathies (Sevy et al., 2015). Most patients included in this study
had previously undergone genetic testing for a number of myopathy-
causing candidate genes. Thus, if our targeted exome approach is ap-
plied to a previously unexplored cohort, the diagnostic rate is expected
to be even higher. Moreover, improvement in coverage and increase in
gene number inMyoPanel2 will further advance the efﬁciency of genet-
ic diagnosis. One obvious limitation of the targeted exome approach is
that this test only detects mutations in genes previously implicated in
the studied disease. If a mutation responsible for patient's phenotype
is located in a novel gene, genetic diagnosis by this approach will not
be possible. In this case, whole exome sequencing might provide diag-
nosis since it is designed to explore all protein coding genes, including
little studied or uncharacterized candidate genes. However, both
targeted exome or whole exome approaches are not the optimal diag-
nostic sequencing test choices for diseases that are often caused by
structural rearrangements or large copy number variations in genomic
sequence. Whole genome sequencing would be more appropriate in
these cases. Given recent results from different studies applying mas-
sively parallel sequencing to diagnosis of myopathies (Gorokhova
et al., 2015), exome based approach is likely to capture a large propor-
tion of disease causingmutations in this group of disorders. The currentpilot study now suggests that an optimized targeted exome approach is
a sensitive and cost effective way to diagnose neuromuscular genetic
disorders.
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